Skip to main content

Table 5 Association of HDAC3 expression with various clinicopathological factors

From: Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

Characteristic All cases HDAC 3 low (IRS 0–4) HDAC 3 intermediate (IRS 6–8) HDAC 3 high (IRS 9–12) P-value χ 2-test for trends
All cases 224 (100%) 80 (35.7%) 73 (32.6%) 71 (31.6%) --
Histological type      0.34
Ductal carcinoma/Other 185 (100%) 69 (37.2%) 58 (31.4%) 58 (31.4%)  
Lobular carcinoma 35 (100%) 10 (28.6%) 12 (34.3%) 13 (37.1%)  
Histological grade      <0.001*
G1 63 (100%) 32 (50.8%) 19 (30.2%) 12 (19%)  
G2 101 (100%) 33 (32.7%) 35 (34.6%) 33 (32.7%)  
G3 56 (100%) 14 (25%) 16 (28.6%) 26 (46.4%)  
Nodal status      0.61
negative 133 (100%) 51 (38.3%) 39 (29.3%) 43 (32.4%)  
positive 78 (100%) 26 (33.3%) 26 (33.3%) 26 (33.3%)  
pT-Stage      0.55
pT1 119 (100%) 43 (36.1%) 37 (31.1%) 39 (32.8%)  
pT2/pT3 87 (100%) 28 (32.2%) 29 (33.3%) 30 (34.5%)  
pT4 13 (100%) 7 (53.8%) 4 (30.8%) 2 (15.4%)  
Hormone receptor status      0.04*
Hormone receptor positive 176 (100%) 65 (36.9%) 63 (35.8%) 48 (27.3%)  
Hormone receptor negative 43 (100%) 14 (32.6%) 7 (16.3%) 22 (51.2%)  
HER2 status      0.12
negative 191 (100%) 71 (37.2%) 63 (35.8%) 48 (27.3%)  
positive 25 (100%) 8 (32%) 4 (16%) 13 (52%)